← Eichor
Study identifier: NCT06474676 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Condition: Metastatic Soft-tissue Sarcoma  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants40
Who can joinAll sexes, 12 Years to no upper limit
Healthy volunteersNo

About this study

To find a recommended dose of attIL2-TIL cell therapy that can be given to participant with either relapsed or metastatic sarcomas (has come back or spread to other parts of the body, respectively). To further test the dose found in Part A to see if it can help to control liposarcoma growth.

This description comes directly from the study's public registry record.

Talk to the study team

Neeta Somaiah, MBBS  ·  (713) 792-3626  ·  nsomaiah@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06474676